SI1849470T1 - Zdravilo proti raku, ki vsebuje alfa,alfa,alfa-trifluorotimidin in zaviralec timidin-fosforilaze - Google Patents

Zdravilo proti raku, ki vsebuje alfa,alfa,alfa-trifluorotimidin in zaviralec timidin-fosforilaze

Info

Publication number
SI1849470T1
SI1849470T1 SI200632192T SI200632192T SI1849470T1 SI 1849470 T1 SI1849470 T1 SI 1849470T1 SI 200632192 T SI200632192 T SI 200632192T SI 200632192 T SI200632192 T SI 200632192T SI 1849470 T1 SI1849470 T1 SI 1849470T1
Authority
SI
Slovenia
Prior art keywords
alpha
trifluorothymidine
anticancer drug
drug containing
phosphorylase inhibitor
Prior art date
Application number
SI200632192T
Other languages
English (en)
Inventor
Tomohiro Emura
Akira Mita
Original Assignee
Taiho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36740357&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1849470(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/042,059 external-priority patent/US7799783B2/en
Application filed by Taiho Pharmaceutical Co., Ltd. filed Critical Taiho Pharmaceutical Co., Ltd.
Publication of SI1849470T1 publication Critical patent/SI1849470T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
SI200632192T 2005-01-26 2006-01-25 Zdravilo proti raku, ki vsebuje alfa,alfa,alfa-trifluorotimidin in zaviralec timidin-fosforilaze SI1849470T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/042,059 US7799783B2 (en) 2005-01-26 2005-01-26 Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
JP2005165156 2005-06-06
EP06712292.9A EP1849470B2 (en) 2005-01-26 2006-01-25 Anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor
PCT/JP2006/301097 WO2006080327A1 (ja) 2005-01-26 2006-01-25 α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤

Publications (1)

Publication Number Publication Date
SI1849470T1 true SI1849470T1 (sl) 2017-10-30

Family

ID=36740357

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200632192T SI1849470T1 (sl) 2005-01-26 2006-01-25 Zdravilo proti raku, ki vsebuje alfa,alfa,alfa-trifluorotimidin in zaviralec timidin-fosforilaze

Country Status (19)

Country Link
EP (1) EP1849470B2 (sl)
JP (1) JP5576591B2 (sl)
KR (1) KR101468216B1 (sl)
AU (1) AU2006209547C1 (sl)
CA (1) CA2594713A1 (sl)
CY (2) CY2017029I2 (sl)
DK (1) DK1849470T4 (sl)
ES (1) ES2630002T3 (sl)
FI (1) FI1849470T4 (sl)
HU (2) HUE033306T2 (sl)
LT (2) LT1849470T (sl)
LU (1) LUC00036I2 (sl)
NL (1) NL300889I2 (sl)
PL (1) PL1849470T3 (sl)
PT (1) PT1849470T (sl)
RU (1) RU2394581C2 (sl)
SI (1) SI1849470T1 (sl)
TW (1) TWI362265B (sl)
WO (1) WO2006080327A1 (sl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
RU2394581C2 (ru) 2005-01-26 2010-07-20 Тайхо Фармасьютикал Ко., Лтд. ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
JP5852309B2 (ja) * 2007-04-25 2016-02-03 サイクラセル リミテッド 増殖性疾患を治療するためのサパシタビンの使用
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
SI2273983T1 (sl) 2008-05-09 2016-11-30 Gruenenthal Gmbh Postopek za pripravo intermediatne praškaste formulacije in končne trdne odmerne oblike z uporabo stopnje strjevanja z razprševanjem
CA2723944A1 (en) * 2008-05-15 2009-11-19 Jan Balzarini Anti-cancer combination therapy
JP5667183B2 (ja) 2009-07-22 2015-02-12 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 加熱溶融押出成型した制御放出性投与剤型
JP2012533585A (ja) 2009-07-22 2012-12-27 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 酸化感受性オピオイドのための不正使用防止剤形
ES2486791T3 (es) 2010-09-02 2014-08-19 Grünenthal GmbH Forma de dosificación resistente a la manipulación que comprende una sal inorgánica
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
US20130028972A1 (en) 2011-07-29 2013-01-31 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
AR087360A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato
SI2746404T1 (sl) * 2011-08-16 2018-04-30 Taiho Pharmaceutical Co., Ltd. Antitumorsko sredstvo in terapevtski efekt napovedne metode za paciente s kras-mutiranim kolorektalnim rakom
TWI503122B (zh) * 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
TWI526210B (zh) * 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
BR112014019988A8 (pt) 2012-02-28 2017-07-11 Gruenenthal Gmbh Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
JP6030119B2 (ja) 2012-03-14 2016-11-24 日清ファルマ株式会社 含硫アミノ酸含有組成物
ES2692944T3 (es) 2012-04-18 2018-12-05 Grünenthal GmbH Forma de dosificación farmacéutica resistente a la manipulación y resistente a la descarga rápida de la dosis
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10213432B2 (en) 2012-05-16 2019-02-26 Novartis Ag Dosage regimen for a PI-3 kinase inhibitor
ES2824400T3 (es) * 2013-03-27 2021-05-12 Taiho Pharmaceutical Co Ltd Agente antitumoral que incluye clorhidrato de irinotecán hidratado
AU2014245147B2 (en) * 2013-03-27 2017-08-31 Taiho Pharmaceutical Co., Ltd. Antitumor agent including low-dose irinotecan hydrochloride hydrate
JP6312660B2 (ja) * 2013-05-17 2018-04-18 大鵬薬品工業株式会社 Ｔｋ１タンパク質の発現が亢進した結腸直腸癌患者に対する治療効果予測方法
BR112015026549A2 (pt) 2013-05-29 2017-07-25 Gruenenthal Gmbh forma de dosagem à prova de violação contendo uma ou mais partículas
WO2014191396A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
CN105682643B (zh) 2013-07-12 2019-12-13 格吕伦塔尔有限公司 含有乙烯-醋酸乙烯酯聚合物的防篡改剂型
PL3042669T3 (pl) 2013-09-06 2023-06-26 Taiho Pharmaceutical Co., Ltd. Środek przeciwnowotworowy i środek wzmacniający efekt przeciwnowotworowy
CA2931553C (en) 2013-11-26 2022-01-18 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of cryo-milling
AU2015261060A1 (en) 2014-05-12 2016-11-03 Grunenthal Gmbh Tamper resistant immediate release capsule formulation comprising Tapentadol
AU2015266117A1 (en) 2014-05-26 2016-11-24 Grunenthal Gmbh Multiparticles safeguarded against ethanolic dose-dumping
MX2017013637A (es) 2015-04-24 2018-03-08 Gruenenthal Gmbh Forma de dosificacion resistente a alteraciones con liberacion inmediata y resistencia contra la extraccion por solventes.
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
RU2747480C2 (ru) * 2016-01-08 2021-05-05 Тайхо Фармасьютикал Ко., Лтд. Противоопухолевое средство, содержащее иммуномодулятор и усилитель противоопухолевого эффекта
NZ745113A (en) * 2016-02-05 2021-12-24 Taiho Pharmaceutical Co Ltd Method for treating cancer patients with severe renal impairment
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
WO2019124544A1 (ja) 2017-12-22 2019-06-27 大鵬薬品工業株式会社 トリフルリジン及び／又はチピラシル由来の類縁物質の検出方法
US10816517B2 (en) 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE245631T1 (de) 1995-03-29 2003-08-15 Taiho Pharmaceutical Co Ltd Uracilderivate und diese enthaltende antitumoreffekt-verstärker sowie antitumormittel
KR100284413B1 (ko) * 1996-09-24 2001-03-02 고바야시 유키오 우라실 유도체를 함유하는 암전이 억제제유도체
RU2394581C2 (ru) 2005-01-26 2010-07-20 Тайхо Фармасьютикал Ко., Лтд. ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ

Also Published As

Publication number Publication date
AU2006209547B2 (en) 2011-05-26
RU2007132181A (ru) 2009-03-10
EP1849470A1 (en) 2007-10-31
PL1849470T3 (pl) 2017-11-30
TW200637562A (en) 2006-11-01
CY1119393T1 (el) 2018-02-14
LTPA2017024I1 (lt) 2017-08-10
AU2006209547A1 (en) 2006-08-03
ES2630002T3 (es) 2017-08-17
CY2017029I1 (el) 2018-02-14
KR101468216B1 (ko) 2014-12-03
WO2006080327A1 (ja) 2006-08-03
EP1849470B2 (en) 2024-03-20
LTC1849470I2 (lt) 2019-10-25
TWI362265B (en) 2012-04-21
LUC00036I2 (sl) 2017-12-01
HUS1700032I1 (hu) 2017-09-28
DK1849470T3 (en) 2017-08-14
NL300889I1 (nl) 2017-08-14
JP5576591B2 (ja) 2014-08-20
HUE033306T2 (hu) 2017-11-28
EP1849470A4 (en) 2010-12-08
LT1849470T (lt) 2017-07-25
KR20070104559A (ko) 2007-10-26
LUC00036I1 (sl) 2017-10-02
CA2594713A1 (en) 2006-08-03
DK1849470T4 (en) 2024-04-02
RU2394581C2 (ru) 2010-07-20
PT1849470T (pt) 2017-09-22
AU2006209547C1 (en) 2022-04-07
CY2017029I2 (el) 2018-02-14
JPWO2006080327A1 (ja) 2008-06-19
FI1849470T4 (fi) 2024-03-22
EP1849470B1 (en) 2017-06-21
NL300889I2 (nl) 2018-01-16

Similar Documents

Publication Publication Date Title
FI1849470T4 (fi) Syövän vastainen lääke sisältäen alfa,alfa,alfa-trifluoritymidiiniä ja tymidiinifosforylaasin estäjää
PL1913001T3 (pl) (R)-N-Metylonaltrekson, sposoby jego syntezy i jego zastosowanie farmaceutyczne
EP1934820A4 (en) DISTRIBUTED INTERMEDIATE STORAGE
IL195488A (en) Compounds, pharmaceuticals containing them and their uses
ZA200709856B (en) Fluorene derivatives,compositions containing said derivatives and the use thereof
IL194751A0 (en) Drugs and uses
AP2008004533A0 (en) Pharmaceutical combination
SI2057153T1 (sl) (3-ril-piperazin-1-il) derivati 6,7-dialkoksikuinazolin, 6,7-dialkoksiftalazin in 6,7-dialkoksiizokuinolin
EP2034015A4 (en) IMMUNOSTIMULATING OLIGONUCLEOTIDE AND ITS PHARMACEUTICAL APPLICATION
EP1863800A4 (en) SYNTHESIS OF AVRAINVILLAMIDE, STEPHACIDINE B AND CORRESPONDING ANALOGUES
EP2005306A4 (en) COMPARISON AND MATCHING PERMUTATION OPERATIONS
GB0516069D0 (en) Pharmaceutical and use thereof
ZA200900673B (en) 18-methyl-19-nor-androst-4-en-17, 17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-one) and pharmaceutical preparations containing the same
IL198236A0 (en) Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
EP2025667A4 (en) 9, 10-SECOPREGNANDERIVAT AND MEDICINAL PRODUCTS
PL1791872T3 (pl) Biotynylowane heksadekasacharydy, kompozycje farmaceutyczne i ich zastosowanie
EP1915988A4 (en) COMPRESSOR COMPRISING MULTIPLE SEGMENTS CONTAINING MEDICAMENTS
IL177759A0 (en) Cospeptin, cosmedin and their uses
ZA200804666B (en) Pharmaceutical combination
IL186851A0 (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
ZA201005396B (en) 17-hydroxy-19-nor-21-carboxylic acid-steroid y-lactone derivative,use thereof,and medicament containing the derivative
TWI372053B (en) Combination drug
IL191618A0 (en) N-hydroxyamide derivatives, their preparation and use
AP2008004389A0 (en) Pharmaceutical combinations containing lamivudine,stavudine,stavudine and navirapine
IL187419A0 (en) Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents